Strategy
MSTR
MARA Holdings
MARA
Petroleo Brasileiro SA Petrobras
PBR
4
Adobe
ADBE
5
Vale SA
VALE
US Stock MarketDetailed Quotes
APVO Aptevo Therapeutics
- 2.410
- +0.030+1.26%
Close Mar 14 16:00 ET
- 2.470
- +0.060+2.49%
Post 17:10 ET
3.51MMarket Cap-0.03P/E (TTM)
2.480High2.410Low6.61KVolume2.410Open2.380Pre Close16.14KTurnover0.45%Turnover RatioLossP/E (Static)1.46MShares207.33352wk High0.74P/B3.51MFloat Cap2.35452wk Low--Dividend TTM1.46MShs Float144729.200Historical High--Div YieldTTM2.94%Amplitude2.354Historical Low2.444Avg Price1Lot Size
About Aptevo Therapeutics Company
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
Company Profile
SymbolAPVO
Company NameAptevo Therapeutics
Listing DateJul 20, 2016
Issue Price3.71
Founded2016
CEOMr. Marvin L. White
MarketNASDAQ
Employees42
Fiscal Year Ends12-31
Address2401 4th Avenue,Suite 1050
CitySeattle
ProvinceWashington
CountryUnited States of America
Zip Code98121
Phone1-206-838-0500
Company Executives
- Name
- Position
- Salary
- Marvin L. White
- Director, President and Chief Executive Officer
- --
- Daphne L. Taylor
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Jeffrey G. Lamothe
- Executive Vice President and Chief Operating Officer
- --
- So Young Kwon
- Senior Vice President, Business Development and Corporate Affairs and General Counsel
- --
- Dr. John E. Niederhuber, M.D.
- Chairman of the Board
- --
- Daniel J. Abdun-Nabi
- Independent Director
- --
- Barbara Lopez Kunz
- Independent Director
- --
- Dr. Zsolt Harsanyi,PhD
- Independent Director
- --
- Grady Grant, III
- Independent Director
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!